Dara Calleary
Ceist:996. Deputy Dara Calleary asked the Minister for Health if there are plans to add a medication (details supplied) to the GMS scheme. [54524/22]
Amharc ar fhreagraTuesday, 8 November 2022
Ceisteanna (996)
Freagraí scríofa
The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drugs schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.
HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds, on the advice of the National Centre for Pharmacoeconomics (NCPE). There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and/or reimbursed.
To be included on the list of reimbursable items the medicinal product must have a marketing authorisation, as per Schedule 3 Part 1 of the Health (Pricing and Supply of Medical Goods) Act 2013.
Semaglutide (marketed as Ozempic®, Wegovy® and Rybelsus®) currently does not have a marketing authorisation for the treatment of Polycystic Ovary Syndrome.